

Notice of Commencement of Phase I Clinical Trial of "DW-1001" in Japan

- The company announced that ROHTO Pharmaceutical Co., Ltd., out-licensor of development product "DW-1001," informed DWTI that they have initiated a Phase I clinical trial in Japan in healthy adults. The company is developing this compound, which is already on the market for the treatment of other diseases, as a treatment for specific diseases in the field of ophthalmology. DWTI acquired the Japanese rights from a UK company in 2015 and licensed them out to ROHTO in 2019.
- Based on the results of non-clinical studies to date, which have confirmed the efficacy and safety of the drug, the company will evaluate the safety and pharmacokinetics of the drug in healthy adults during single and repeated dosing in the study. Rohto's development code is "ROH-202." Upon commencement of the study, DWTI will receive a milestone payment from Rohto under the terms of the agreement. The milestone payment has already been included in the financial forecast for the fiscal year ending December 31, 2022.
- DWTI is seeking to develop new drugs by expanding the indications of compounds already on the market to other disease types. The expected benefits of this so-called repositioning approach are relatively low development costs and risks.

DW-1001

Clinical indication	Ophthalmic treatment agent (non-disclosure)
Development process	Phase I clinical trials (Japan) started
Licensee	ROHTO Pharmaceutical Co., Ltd.

Development Progress

2022.03	Phase I clinical trials (Japan) started
2019.12	Licensed out rights of Japan to ROHTO Pharmaceutical Co., Ltd.
2015.06	In-licensed rights of Japan from British Co.

Source: compiled by Sessa Partners from company March 28 press release.

News Flash



D. WESTERN THERAPEUTICS INSTITUTE

Focus Points:

Drug discovery bio-venture with strengths in the kinase inhibitor mechanism and treatments for ophthalmic diseases such as glaucoma and ocular hypertension.

Chris Schreiber CFA

Company Specialist
research@sessapartners.co.jp



This report was prepared by Sessa Partners on behalf of D. Western Therapeutics Institute, Inc. Please refer to the legal disclaimer at the end for details.

LEGAL DISCLAIMER

This report is intended to provide information about the subject company, and it is not intended to solicit or recommend investment. Although the data and information contained in this report have been determined to be reliable, we do not guarantee their authenticity or accuracy.

This report has been prepared by Sessa Partners on behalf of the concerned company for which it has received compensation. Officers and employees of Sessa Partners may be engaged in transactions such as trading in securities issued by the company, or they may have the possibility of doing so in the future. For this reason, the forecasts and information contained in this report may lack objectivity. Sessa Partners assumes no liability for any commercial loss based on use of this report. The copyright of this report belongs to Sessa Partners. Modification, manipulation, distribution or transmission of this report constitutes copyright infringement and is strictly prohibited.



Sessa Partners Inc.

5-3-18 Hiroo, Shibuya-ku, Tokyo
info@sessapartners.co.jp